Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Ask Michael Burke -- Ignore unavailable to you. Want to Upgrade?

To: Skeeter Bug who wrote (90401)	3/22/2001 1:45:32 PM
From: Thomas M.	Read Replies (1) \| Respond to of 132070

The plan was to improve the existing drug, and then sell these rights to the manufacturer of the original as a sort of patent extension. The idea was to sell at full price, not generic. Their main drug, Xopenex - a purer version of current asthma mainstays Ventolin/Proventil, is gaining market share despite the presence of generic competition. It is gaining because it has fewer side effects. They are the creators of Allegra, which is basically a derivative of Seldane. They eliminated the risk of heart attacks from Seldane. They get a royalty (I think 8%) from HMR. why did the big boys with the high powered researchers drop sepr's goods? That's the million dollar question. JNJ dropped one of SEPR's antihistamines for reasons unknown, though they are sticking with the Propulsid project. Schering didn't drop SEPR, they just dropped the ball. They are in the doghouse with the FDA, which is hurting the prospects of SEPR's Claritin derivative. Some basic info: sepracor.com Tom